ArticleMolecular imaging and biology2014
Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.
Article in Molecular imaging and biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.Radiology. Imaging cancer · 2022Trial
- Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- Prediction ofCancers · 2023Article
- SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity.Scientific reports · 2022Article
- Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters.Biomedicines · 2022Article
- A decade of multi-modality PET and MR imaging in abdominal oncology.The British journal of radiology · 2021Review
- Radiopharmaceutical Chemistry and Drug Development-What's Changed?Seminars in radiation oncology · 2021Review
- Development of NovelBiomolecules · 2020Article
- (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy withContrast media & molecular imaging · 2019Article
- Potentials and challenges of diffusion-weighted magnetic resonance imaging in radiotherapy.Clinical and translational radiation oncology · 2018Review
- Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.The British journal of radiology · 2017Review
- Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Review
- Article
- Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.Cancer metastasis reviews · 2015Review
- [Radionuclide therapy of endocrine-related cancer].Der Radiologe · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe purpose of this study is to investigate the utility of contrast-enhanced magnetic resonance imaging (CE-MRI), diffusion-weighted MRI (DW-MRI), and (68)Ga-DOTATOC positron emission tomography/computer tomography ((68)Ga-DOTATOC PET/CT) in the assessment of response to loco-regional peptide receptor radiotherapy (PRRT) with (90)Y-/(177)Lu-DOTATOC in patients with hepatic metastases from gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). PROCEDURES: CE-MRI, DW-MRI, and (68)Ga-DOTATOC-PET/CT images were acquired before and 3 months after one to two cycles of intra-arterial (90)Y-/(177)Lu-DOTATOC therapy in 14 patients (nine female, five male; mean age, 54 ± 9 years; range, 41-69 years) with hepatic metastases from GEP-NET. A total of 38 liver metastases were defined as target lesions for which the longest diameter, mean apparent diffusion coefficient (ADCmean) and maximum standardized uptake value (SUVmax) were assessed. Based on changes in size on follow-up imaging, target lesions were classified as responding (RL) or nonresponding (NRL). Relative changes in tumor size, ADCmean, and SUVmax were compared between the two subgroups.
resultsA total of 27 responding and 11 nonresponding lesions were successfully evaluated. Mean ADCmean increased significantly in RL (p = 0.011) as well as NRL (p = 0.025). A significant correlation was found between baseline ADCmean and both the percent ADCmean change (p = 0.033) and decrease in lesion size after therapy (diameter p = 0.006; volume p = 0.002). SUVmax of RL declined significantly by 24.1 % (p = 0.014) and remained nearly unchanged in NRL. The change of SUVmax correlated significantly with the pretreatment SUVmax (p < 0.001) and the change in lesion diameter (p = 0.009). NRL with an ADCmean change >0.31 × 10(-3) mm(2)/s on first follow-up imaging showed a decrease in size in the long-term course.
conclusionThese results suggest that both DW-MRI and DOTATOC-PET imaging provide potential biomarkers for early assessment of treatment and stratification of therapy response, but that DW-MRI should be interpreted only in combination with SSTR expression and morphologic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.